Genetic polymorphism of metallothionein 2A and risk of laryngeal cancer in a Polish population

被引:16
作者
Starska, Katarzyna [1 ]
Krzeslak, Anna [2 ]
Forma, Ewa [2 ]
Olszewski, Jurek [3 ]
Lewy-Trenda, Iwona [4 ]
Osuch-Wojcikiewicz, Ewa [5 ]
Brys, Magdalena [2 ]
机构
[1] Med Univ Lodz, Dept Otolaryngol & Laryngol Oncol 1, PL-90153 Lodz, Poland
[2] Univ Lodz, Dept Cytobiochem, PL-90236 Lodz, Poland
[3] Med Univ Lodz, Dept Otolaryngol & Laryngol Oncol 2, PL-90549 Lodz, Poland
[4] Med Univ Lodz, Dept Pathol, PL-92213 Lodz, Poland
[5] Med Univ Warsaw, Dept Otolaryngol & Laryngol Oncol, PL-02097 Warsaw, Poland
关键词
Metallothionein 2A (MT2A); Single-nucleotide polymorphism (SNP); Tumor front grading (TFG); Laryngeal cancer; SINGLE-NUCLEOTIDE POLYMORPHISM; SQUAMOUS-CELL CARCINOMA; STRESS-RELATED GENES; PROSTATE-CANCER; BREAST-CANCER; EXPRESSION; PROMOTER; CADMIUM;
D O I
10.1007/s12032-014-0075-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metallothioneins are intracellular regulators of many biological mechanisms including differentiation, proliferation, angiogenesis and invasion, which are crucial processes in carcinogenesis. This study examines the association between three single-nucleotide polymorphisms at loci -5 A/G (rs28366003) and -209 A/G (rs1610216) in the core promoter region and at locus +838 C/G (rs10636) in 3'UTR region of the metallothionein 2A (MT2A) gene with squamous cell laryngeal cancer (SCLC) risk, as well as with tumor invasiveness according to tumor front grading (TFG). Genotyping was performed using the polymerase chain reaction-restriction fragment length polymorphism technique in 323 genetically unrelated individuals with SCLC and 418 randomly selected healthy volunteers. Only one SNP (rs28366003) was significantly related to laryngeal cancer in the study population. Compared with homozygous common allele carriers, heterozygous and homozygous for the G variant had significantly increased risk of SCLC [adjusted odds ratio (OR) = 2.90, 95 % confidence interval (CI) 1.53-5.21, p(dominant) < 0.001]. The A/G allele carriers at rs28366003 MT2A were at higher risk of SCLC development (OR = 2.63, 95 % CI 1.41-2.85, p < 0.001]. There was a significant association between the rs28366003 and stage and TFG classification. Most carriers of minor allele had a higher stage (OR = 2.76, 95 % CI 1.11-7.52, p = 0.03), increased cancer aggressiveness, as defined by a higher total TFG score ([18 points) (OR = 3.76, 95 % CI 1.15-12.56, p = 0.03) and diffuse tumor growth (OR = 5.86, 95 % CI 0.72-44.79, p = 0.08). The results of this study raise a possibility that a genetic variation of MT2A may be implicated in the etiology of laryngeal cancer in a Polish population.
引用
收藏
页数:10
相关论文
共 37 条
[1]   Mammalian metallothioneins: properties and functions [J].
Babula, Petr ;
Masarik, Michal ;
Adam, Vojtech ;
Eckschlager, Tomas ;
Stiborova, Marie ;
Trnkova, Libuse ;
Skutkova, Helena ;
Provaznik, Ivo ;
Hubalek, Jaromir ;
Kizek, Rene .
METALLOMICS, 2012, 4 (08) :739-750
[2]   Adenoid cystic carcinoma of the salivary gland: a clinicopathological study of 49 cases and of metallothionein expression with regard to tumour behaviour [J].
Brazao-Silva, Marco Tullio ;
Cardoso, Sergio Vitorino ;
de Faria, Paulo Rogerio ;
Dias, Fernando Luiz ;
Lima, Roberto Araujo ;
Amaral Eisenberg, Ana Lucia ;
Nascimento, Marilena Filgueira ;
Loyola, Adriano Mota .
HISTOPATHOLOGY, 2013, 63 (06) :802-809
[3]  
Dutsch-Wicherek M, 2005, NEUROENDOCRINOL LETT, V26, P567
[4]   The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM [J].
Edge, Stephen B. ;
Compton, Carolyn C. .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (06) :1471-1474
[5]   Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a Polish population [J].
Forma, Ewa ;
Krzeslak, Anna ;
Wilkosz, Jacek ;
Jozwiak, Pawel ;
Szymczyk, Agnieszka ;
Rozanski, Waldemar ;
Brys, Magdalena .
CANCER GENETICS, 2012, 205 (09) :432-435
[6]   Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway [J].
Fu, Jiao ;
Lv, Hongjun ;
Guan, Haixia ;
Ma, Xiaoying ;
Ji, Meiju ;
He, Nongyue ;
Shi, Bingyin ;
Hou, Peng .
BMC CANCER, 2013, 13
[7]  
Gansukh T, 2013, ANTICANCER RES, V33, P5255
[8]   Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle [J].
Gumulec, Jaromir ;
Balvan, Jan ;
Sztalmachova, Marketa ;
Raudenska, Martina ;
Dvorakova, Veronika ;
Knopfova, Lucia ;
Polanska, Hana ;
Hudcova, Kristyna ;
Ruttkay-Nedecky, Branislav ;
Babula, Petr ;
Adam, Vojtech ;
Kizek, Rene ;
Stiborova, Marie ;
Masarik, Michal .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 44 (03) :923-933
[9]   Metallothionein - Immunohistochemical Cancer Biomarker: A Meta-Analysis [J].
Gumulec, Jaromir ;
Raudenska, Martina ;
Adam, Vojtech ;
Kizek, Rene ;
Masarik, Michal .
PLOS ONE, 2014, 9 (01)
[10]   Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance [J].
Habel, N. ;
Hamidouche, Z. ;
Girault, I. ;
Patino-Garcia, A. ;
Lecanda, F. ;
Marie, P. J. ;
Fromigue, O. .
CELL DEATH & DISEASE, 2013, 4 :e874-e874